IDS and mucopolysaccharidosis type 2: Intravenous enzyme replacement therapy with recombinant human I2S (idursulfase (Elaprase) Shire, Lexington, MA) is an approved treatment for Hunter syndrome [4] and is currently available in over 50 countries.